What Is LADA (Type 1.5 Diabetes)? Symptoms and How It Differs from Type 1 and Type 2

LADA (type 1.5 diabetes) is autoimmune diabetes that develops slowly in adults, often misdiagnosed as type 2. Learn the symptoms, tests, and treatment.

LADA (Latent Autoimmune Diabetes in Adults) is a form of autoimmune diabetes that develops slowly in adults, typically between ages 30–50. It is often misdiagnosed as type 2 diabetes because it presents in adulthood and initial blood sugar control may respond to oral medications. However, it is caused by the same immune attack on beta cells as type 1 diabetes and eventually requires insulin. It is sometimes called type 1.5 diabetes.

At a Glance

• LADA accounts for approximately 2–12% of all adult-onset diabetes diagnoses.
• It is caused by autoimmune destruction of insulin-producing beta cells — the same mechanism as type 1 diabetes.
• Unlike type 1, the autoimmune process is slow — taking months to years to destroy all beta cells.
• It is initially diagnosed as type 2 because it occurs in adults and may respond temporarily to oral medications.
• It is diagnosed by testing for diabetes autoantibodies — GAD antibodies are present in 70–80% of LADA cases.
• LADA eventually requires insulin — usually within 6 years of diagnosis.

What Is LADA?

LADA stands for Latent Autoimmune Diabetes in Adults. The immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas, as in type 1 diabetes — but the process is much slower, unfolding over months or years rather than weeks. This gradual onset means many people with LADA initially appear to have type 2 diabetes and are treated accordingly. Over time, as more beta cells are destroyed, oral medications become insufficient and insulin is required.

How LADA Differs from Type 1 and Type 2 Diabetes

• vs Type 1: both are autoimmune; type 1 destroys beta cells rapidly (weeks to months), LADA destroys them slowly (months to years).
• Type 1 typically presents in childhood or adolescence; LADA presents in adults (30s–50s); both eventually require insulin.
• vs Type 2: type 2 is caused by insulin resistance and insufficient insulin production — not autoimmune; type 2 can often be managed long-term with lifestyle changes and oral medication.
• LADA eventually fails on oral-only therapy regardless of lifestyle, whereas type 2 may be managed without insulin for many years.
• Body weight: type 2 is strongly associated with excess weight; LADA is more common in normal-weight adults.
• Family history: LADA may be associated with a type 1 or autoimmune family history rather than a type 2 history.

Symptoms of LADA

Symptoms of LADA overlap with both type 1 and type 2 diabetes and often appear gradually. Because the autoimmune process is slow, some people live with LADA for months or years before blood sugar rises enough to cause noticeable symptoms. Key warning signs include:

• Excessive thirst and frequent urination.
• Unexplained weight loss — more prominent than in a typical type 2 presentation.
• Fatigue and weakness.
• Blurred vision.
• Slow-healing wounds.
• Normal or below-average body weight at diagnosis — unlike the typical type 2 presentation.
• Treatment failure: blood sugar that is initially controlled by oral medication but progressively worsens despite increasing doses — a key LADA clue.

How Is LADA Diagnosed?

LADA is frequently missed because autoantibody testing is not part of the standard diabetes workup for adults. A specific autoantibody test is required to distinguish LADA from type 2 diabetes. Clinicians should consider LADA in adults who do not fit the typical type 2 profile or who fail to respond to standard treatment.

• GAD antibody test (glutamic acid decarboxylase antibodies): present in 70–80% of LADA cases; negative in type 2 diabetes. IA-2 antibodies and ZnT8 antibodies may also be positive.
• C-peptide test: measures how much insulin the pancreas is still producing. Low or declining C-peptide suggests autoimmune beta cell destruction.
• Who should be tested: adults diagnosed with type 2 who are lean, do not improve with oral medications, or have other autoimmune conditions such as thyroid disease or coeliac disease.
• LADA should be suspected when type 2 treatments fail within 6 years of diagnosis.
• A combination of positive autoantibodies, adult age of onset, and declining beta cell function (low C-peptide) together confirms the diagnosis.

Treatment for LADA

Treatment for LADA evolves as beta cell function declines. Importantly, early treatment choices can influence how quickly remaining beta cells are lost — making early, accurate diagnosis particularly valuable.

• Early stage (some insulin production remaining): some evidence suggests that early insulin therapy protects remaining beta cells better than sulfonylureas, which may accelerate their loss.
• Sulfonylureas (glipizide, gliclazide) should generally be avoided in LADA — they stimulate already-stressed beta cells and may hasten their destruction.
• Metformin can be used in early LADA if metabolic features overlap with type 2 diabetes.
• Insulin becomes necessary as C-peptide levels drop — the timeline varies but most people require insulin within 2–6 years of LADA diagnosis.
• Blood sugar monitoring: more intensive monitoring than typical type 2 is warranted — as insulin production declines, blood sugar becomes less predictable and harder to control with oral agents alone.

LADA and Associated Autoimmune Conditions

• People with LADA have higher rates of other autoimmune conditions than people with type 2 diabetes.
• Autoimmune thyroid disease (Hashimoto's thyroiditis, Graves' disease): a common co-occurrence that warrants thyroid screening at diagnosis.
• Coeliac disease: approximately 5–10% of people with type 1 diabetes or LADA also have coeliac disease.
• Addison's disease (autoimmune adrenal insufficiency): less common but occurs at higher rates in people with autoimmune diabetes.
• Vitiligo (autoimmune skin depigmentation): shares the same autoimmune background and appears more frequently in people with LADA.

Living with LADA

• Monitor blood sugar closely — because beta cell function declines over time, readings that were previously stable may begin to fluctuate.
• Be prepared for insulin: the transition to insulin is not a sign of failure — it reflects the natural disease progression in LADA.
• Blood sugar control targets and management evolve: work with your diabetes care team to adjust your plan as beta cell function changes.
• Wear a medical ID indicating your diabetes type — LADA is not always well-understood in emergency settings.
• Connect with type 1 and LADA communities — the daily management experience is closer to type 1 than type 2.

Frequently Asked Questions

How common is LADA?

LADA is estimated to account for 2–12% of all diabetes diagnoses in adults, making it significantly more common than is generally recognised. In studies of adults newly diagnosed with type 2 diabetes, LADA is found in approximately 5–10% when antibody testing is performed. It is more common in leaner adults and those with autoimmune family histories. Because specific antibody testing is not routine, many cases remain misdiagnosed as type 2 for years.

Can LADA be prevented?

No — LADA is an autoimmune condition driven by genetic susceptibility and environmental triggers that are not yet fully understood. Unlike type 2 diabetes, it cannot be prevented through lifestyle changes such as weight loss or diet. Research into preventing autoimmune beta cell destruction (similar to type 1 prevention research) is ongoing, but no proven intervention exists yet.

Will I definitely need insulin if I have LADA?

Yes — eventually. Because the autoimmune process destroys beta cells progressively, insulin production declines over time. Most people with LADA require insulin within 2–6 years of diagnosis, though some maintain residual beta cell function for longer. Early insulin therapy may actually slow beta cell loss in LADA. Unlike type 2 diabetes, LADA does not plateau — oral medications become progressively less effective as the autoimmune process continues.

Sources

• American Diabetes Association (ADA) — diabetes.org
• Diabetes UK — diabetes.org.uk
• National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) — niddk.nih.gov
• Mayo Clinic — mayoclinic.org

← Back to all articles